BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26330387)

  • 21. Molecular analysis of isolated tumor glands from endometrial endometrioid adenocarcinomas.
    Suga Y; Sugai T; Uesugi N; Kawasaki T; Fukagawa T; Yamamoto E; Ishida K; Suzuki H; Sugiyama T
    Pathol Int; 2015 May; 65(5):240-9. PubMed ID: 25824640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
    Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS
    Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
    Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
    Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers.
    Maxwell GL; Risinger JI; Alvarez AA; Barrett JC; Berchuck A
    Obstet Gynecol; 2001 Mar; 97(3):417-22. PubMed ID: 11239648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
    Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
    Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.
    Le Gallo M; Rudd ML; Urick ME; Hansen NF; Zhang S; ; Lozy F; Sgroi DC; Vidal Bel A; Matias-Guiu X; Broaddus RR; Lu KH; Levine DA; Mutch DG; Goodfellow PJ; Salvesen HB; Mullikin JC; Bell DW
    Cancer; 2017 Sep; 123(17):3261-3268. PubMed ID: 28485815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterization of endometrial cancer and therapeutic implications.
    Uppendahl L; Mullany SA; Winterhoff B
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):35-39. PubMed ID: 27941362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methylation profiles of endometrioid and serous endometrial cancers.
    Seeber LM; Zweemer RP; Marchionni L; Massuger LF; Smit VT; van Baal WM; Verheijen RH; van Diest PJ
    Endocr Relat Cancer; 2010 Sep; 17(3):663-73. PubMed ID: 20488783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
    Lin WM; Forgacs E; Warshal DP; Yeh IT; Martin JS; Ashfaq R; Muller CY
    Clin Cancer Res; 1998 Nov; 4(11):2577-83. PubMed ID: 9829719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-resolution copy number analysis of clear cell endometrial carcinoma.
    O'Hara AJ; Le Gallo M; Rudd ML; Bell DW
    Cancer Genet; 2020 Jan; 240():5-14. PubMed ID: 31678638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
    Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
    Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
    Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
    Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers.
    Mutch DG; Powell MA; Mallon MA; Goodfellow PJ
    Am J Obstet Gynecol; 2004 Apr; 190(4):935-42. PubMed ID: 15118616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer.
    Bilbao C; Rodríguez G; Ramírez R; Falcón O; León L; Chirino R; Rivero JF; Falcón O; Díaz-Chico BN; Díaz-Chico JC; Perucho M
    Int J Cancer; 2006 Aug; 119(3):563-70. PubMed ID: 16506206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma.
    Arafa M; Kridelka F; Mathias V; Vanbellinghen JF; Renard I; Foidart JM; Boniver J; Delvenne P
    Histopathology; 2008 Nov; 53(5):525-32. PubMed ID: 18783461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single nucleotide polymorphism of pi-class glutathione s-transferase and susceptibility to endometrial carcinoma.
    Chan QK; Khoo US; Ngan HY; Yang CQ; Xue WC; Chan KY; Chiu PM; Ip PP; Cheung AN
    Clin Cancer Res; 2005 Apr; 11(8):2981-5. PubMed ID: 15837751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma.
    Baldinu P; Cossu A; Manca A; Satta MP; Pisano M; Casula M; Dessole S; Pintus A; Tanda F; Palmieri G
    Cancer; 2002 Jun; 94(12):3157-68. PubMed ID: 12115348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
    Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
    Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.